Age-related efficacy with an AAV vector in Fabry disease mice

Molecular Genetics and Metabolism

Volumn 96, Issue 3, 2009, Pages 83-84

  Koeberl, Dwight D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; PARVOVIRUS VECTOR;

ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYSOSOME STORAGE DISEASE; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

MUS;

EID: 60649121515     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2008.10.014     Document Type: Note

References (10)

1. Olson C.M., Rennie D., Cook D., Dickersin K., Flanagin A., Hogan J.W., Zhu Q., Reiling J., and Pace B. Publication bias in editorial decision making. JAMA 287 (2002) 2825-2828
2. Ogawa K., Hirai Y., Ishizaki M., Takahashi H., Hanawa H., Fukunaga Y., and Shimada T. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAVI vector in the neonatal period. Mol. Genet. Metab. 96 (2009) 91-96
3. Daly T.M., Vogler C., Levy B., Haskins M.E., and Sands M.S. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Natl. Acad. Sci. USA 96 (1999) 2296-2300
4. Mah C., Cresawn K.O., Fraites T.J., Pacak C.A., Lewis M.A., Zolotukhin I., and Byrne B.J. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther. 12 (2005) 1405-1409
5. Park J., Murray G.J., Limaye A., Quirk J.M., Gelderman M.P., Brady R.O., and Qasba P. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc. Natl. Acad. Sci. USA 100 (2003) 3450-3454
6. Davidoff A.M., Ng C.Y., Zhou J., Spence Y., and Nathwani A.C. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102 (2003) 480-488
7. Sun B., Zhang H., Franco L.M., Young S.P., Schneider A., Bird A., Amalfitano A., Chen Y.T., and Koeberl D.D. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol. Ther. 11 (2005) 57-65
8. Ziegler R.J., Lonning S.M., Armentano D., Li C., Souza D.W., Cherry M., Ford C., Barbon C.M., Desnick R.J., Gao G.P., Wilson J.M., Peluso R., Godwin S., Carter B.J., Gregory R.J., Wadsworth S.C., and Cheng S.H. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol. Ther. 9 (2004) 231-240
9. Ziegler R.J., Cherry M., Barbon C.M., Li C., Bercury S.D., Armentano D., Desnick R.J., and Cheng S.H. Correction of the biochemical and functional deficits in Fabry Mice following AAV8-mediated hepatic expression of alpha-galactosidase A. Mol. Ther. 15 (2007) 492-500
10. Sun B., Bird A., Young S.P., Kishnani P.S., Chen Y.T., and Koeberl D.D. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am. J. Hum. Genet. 81 (2007) 1042-1049